DARPin_9-29-Targeted Mini Gold Nanorods Specifically Eliminate HER2-Overexpressing Cancer Cells

被引:16
|
作者
Proshkina, Galina [1 ]
Deyev, Sergey [1 ]
Ryabova, Anastasiya [2 ]
Tayanti, Francesco [3 ]
Menziani, Maria Cristina [3 ]
Cohen, Roy [4 ,5 ]
Katrivas, Liat [4 ,5 ]
Kotlyar, Alexander [4 ,5 ]
机构
[1] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Miklukho Maklaya St 16-10, Moscow 117997, Russia
[2] Russian Acad Sci, Prokhorov Gen Phys Inst, 38 Vavilova St, Moscow 119991, Russia
[3] Univ Modena & Reggio Emilia, Dept Chem & Geol Sci, Via Campi 103, I-41125 Modena, Italy
[4] Tel Aviv Univ, Dept Biochem & Mol Biol, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel
[5] Tel Aviv Univ, Ctr Nanosci & Nanotechnol, IL-69978 Tel Aviv, Israel
基金
以色列科学基金会; 俄罗斯科学基金会; 俄罗斯基础研究基金会;
关键词
DARPin; gold nanorods; near-infrared illumination; tumor cells; molecular dynamic simulations; COLLOIDAL NANOPARTICLES; MAMMALIAN-CELLS; DELIVERY;
D O I
10.1021/acsami.9b10441
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
We have demonstrated that designed ankyrin repeat protein (DARPin) _9-29, which specifically targets human epidermal growth factor receptor 2 (HER2), binds tightly to gold mini nanorods (GNRs). Molecular dynamic simulations showed that a single layer of DARPin_9-29 molecules is formed on the surface of the nanorod and that conjugation with the nanorod does not involve the protein's domain responsible for specific binding to HER2. The nanorod-DARPin (DARPin-GNR) conjugate is specifically bound (in nanomolar concentrations) to human breast adenocarcinoma SK-BR-3 cells overexpressing HER2. Illumination by near-infrared light (850 nm) led to almost complete eradication of the conjugate-treated SK-BR-3 cells; the viability of epithelial human breast cancer cells expressing normal amounts of the receptor was much less affected by the illumination. The results reported here pave the way toward application of DARPin-GNR conjugates in phototherapy of cancer.
引用
收藏
页码:34645 / 34651
页数:7
相关论文
共 50 条
  • [1] DARPin_9-29-Targeted Gold Nanorods Selectively Suppress HER2-Positive Tumor Growth in Mice
    Proshkina, Galina M.
    Shramova, Elena I.
    Shilova, Marya V.
    Zelepukin, Ivan V.
    Shipunova, Victoria O.
    Ryabova, Anastasia V.
    Deyev, Sergey M.
    Kotlyar, Alexander B.
    CANCERS, 2021, 13 (20)
  • [2] HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells
    Yamaguchi, Haruka
    Hayama, Kazuhide
    Sasagawa, Ichiro
    Okada, Yasuo
    Kawase, Tomoyuki
    Tsubokawa, Norio
    Tsuchimochi, Makoto
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (03)
  • [3] Targeted Therapies in HER2-Overexpressing Metastatic Breast Cancer
    Labidi, Soumaya
    Mejri, Nesrine
    Lagha, Aymen
    Daoud, Nouha
    El Benna, Houda
    Afrit, Mehdi
    Boussen, Hamouda
    BREAST CARE, 2016, 11 (06) : 418 - 422
  • [4] Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
    K Mann
    M Kullberg
    Cancer Gene Therapy, 2016, 23 : 221 - 228
  • [5] Green synthesis of silver nanoparticles for the targeted delivery to HER2-overexpressing cancer cells
    Shipunova, V.
    Belova, M.
    Komedchikova, E.
    Babenyshev, A.
    Deyev, S.
    FEBS OPEN BIO, 2019, 9 : 381 - 381
  • [6] Trastuzumab-targeted gene delivery to Her2-overexpressing breast cancer cells
    Mann, K.
    Kullberg, M.
    CANCER GENE THERAPY, 2016, 23 (07) : 221 - 228
  • [7] Bioconjugated Fluorescent Polymeric Nanoparticles for Imaging and Targeted Therapy of HER2-Overexpressing Cancer Cells
    Tzong-Der Way
    Chi-Jung Chang
    Cheng-Wen Lin
    Journal of Fluorescence, 2011, 21 : 1669 - 1676
  • [8] Bioconjugated Fluorescent Polymeric Nanoparticles for Imaging and Targeted Therapy of HER2-Overexpressing Cancer Cells
    Way, Tzong-Der
    Chang, Chi-Jung
    Lin, Cheng-Wen
    JOURNAL OF FLUORESCENCE, 2011, 21 (04) : 1669 - 1676
  • [9] Trastuzumab-cisplatin conjugates for targeted delivery of cisplatin to HER2-overexpressing cancer cells
    Huang, Rong
    Wang, Qiucui
    Zhang, Xiangyang
    Zhu, Jin
    Sun, Baiwang
    BIOMEDICINE & PHARMACOTHERAPY, 2015, 72 : 17 - 23
  • [10] The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer
    Dent, S.
    Verma, Sh.
    Latreille, J.
    Rayson, D.
    Clemons, M.
    Mackey, J.
    Verma, Su
    Lemieux, J.
    Provencher, L.
    Chia, S.
    Wang, B.
    Pritchard, K.
    CURRENT ONCOLOGY, 2009, 16 (04) : 235 - 245